Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,555,211 shares of the medical equipment provider's stock after selling 226,514 shares during the quarter. Alliancebernstein L.P. owned 1.13% of Hologic worth $184,205,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth about $26,000. Venturi Wealth Management LLC increased its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co grew its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price on the stock. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Morgan Stanley cut their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $0.83 on Friday, hitting $60.86. 6,509,048 shares of the company were exchanged, compared to its average volume of 1,842,488. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock's 50 day moving average price is $64.30 and its 200 day moving average price is $72.59. Hologic, Inc. has a 1-year low of $59.06 and a 1-year high of $84.67. The firm has a market capitalization of $13.66 billion, a P/E ratio of 19.20, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.